SCHEMBL919359

SCHEMBL919359

CNCCCc1cccs1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 2/20 0.55
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.45
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
TSHR P16473 1/20 0.45
GPR84 Q9NQS5 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
PTGS1 P23219 1/20 0.42
PTGS2 P35354 1/20 0.42
ADRA2A P08913 2/20 0.42
ADRA2B P18089 2/20 0.42
ADRA2C P18825 2/20 0.42
SIGMAR1 Q99720 1/20 0.41
MAOB P27338 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL920771 0.94 TAAR1 (0.53) TAAR1MEN1KMT2ASMN1; SMN2NPC1
SCHEMBL919297 0.92 TAAR1 (0.52) TAAR1MEN1KMT2ASMN1; SMN2NPC1
SCHEMBL680547 0.88
Hydrochloric Acid SCHEMBL1027465 0.86 TAAR1 (0.52) TAAR1MEN1KMT2ASMN1; SMN2NPC1
SCHEMBL7533129 0.81 TAAR1 (0.52) TAAR1MEN1KMT2ASMN1; SMN2NPC1
SCHEMBL20135772 0.80 TAAR1 (0.73) TAAR1SMN1; SMN2NPC1RAB9ATSHR
SCHEMBL20146704 0.80 TAAR1 (0.73) TAAR1SMN1; SMN2NPC1RAB9ATSHR
SCHEMBL6685935 0.80 TAAR1 (0.55) TAAR1SMN1; SMN2NPC1RAB9ATSHR
SCHEMBL22067943 0.79 TAAR1 (0.50) TAAR1MEN1KMT2ASMN1; SMN2NPC1
SCHEMBL8571535 0.78 TAAR1 (0.70) TAAR1SMN1; SMN2NPC1RAB9ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111225901-B Propylamine derivatives for the treatment of pain and pain-related disorders 埃斯特韦制药股份公司 2023-07-04 CN claimed
EP-3558983-A1 NITROGEN CONTAINING BICYCLIC DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS ESTEVE PHARMACEUTICALS, S.A. (ES) 2019-10-30 EP claimed
EP-3558965-A1 NEW QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS ESTEVE PHARMACEUTICALS, S.A. (ES) 2019-10-30 EP claimed
WO-2018115069-A1 NITROGEN CONTAINING BICYCLIC DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2018-06-28 WO claimed
WO-2018115064-A1 NEW QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2018-06-28 WO claimed
US-12492195-B2 Preparation method for and crystal form of 3-aryloxy-3-five-membered heteroaryl-propylamine compound ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD. (CN) 2025-12-09 US disclosed
CN-115135644-B Preparation method and crystal form of 3-aryloxy-3-five-membered heteroaryl-propylamine compound 漳州片仔癀药业股份有限公司 2024-06-18 CN disclosed
CN-112654616-B 3-aryloxy-3-aryl-propylamines and application thereof 漳州片仔癀药业股份有限公司 2024-03-12 CN disclosed
CN-111225901-B Propylamine derivatives for the treatment of pain and pain-related disorders 埃斯特韦制药股份公司 2023-07-04 CN disclosed
EP-4105212-A1 PREPARATION METHOD FOR AND CRYSTAL FORM OF 3-ARYLOXY-3-FIVE-MEMBERED HETEROARYL-PROPYLAMINE COMPOUND Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. (CN) 2022-12-21 EP disclosed
EP-4076668-A1 COMPOSITION AND METHOD FOR TREATING DERMATOLOGICAL DISORDERS USING RETINAMIDES University of Maryland, Baltimore (US) 2022-10-26 EP disclosed
CN-115135644-A Preparation method and crystal form of 3-aryloxy-3-pentabasic heteroaryl-propylamine compound 漳州片仔癀药业股份有限公司 2022-09-30 CN disclosed
WO-2009109992-A1 NOVEL PROCESS FOR PREPARATION OF DULOXETINE AND INTERMEDIATES FOR USE THEREIN ARCH PHARMALABS LIMITED (IN) 2009-09-11 WO disclosed
WO-2008126684-A2 AGRICULTURAL COMPOSITION FOR CONTROLLING OR PREVENTING PLANT DISEASES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-10-23 WO disclosed
EP-1263711-B1 NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES ASTRAZENECA AB (SE) 2004-12-15 EP disclosed
US-20040249170-A1 Process for preparing an intermediate useful for the asymmetric synthesis of duloxetine BORGHESE ALFIO (BE) 2004-12-09 US disclosed
EP-1478641-A1 PROCESS FOR PREPARING AN INTERMEDIATE USEFUL FOR THE ASYMMETRIC SYNTHESIS OF DULOXETINE ELI LILLY AND COMPANY (US) 2004-11-24 EP disclosed
WO-2003062219-A1 PROCESS FOR PREPARING AN INTERMEDIATE USEFUL FOR THE ASYMMETRIC SYNTHESIS OF DULOXETINE ELI LILLY AND COMPANY (US) 2003-07-31 WO disclosed
US-4737495-A ANTIALLERGENS, ANTISCHEMIC, HYPOTENSIVE AGENTS DR. KARL TOMAE, GMBH (DE) 1988-04-12 US disclosed
EP-0204349-A2 Heteroaromatic amine derivatives, medicaments containing them and process for their preparation Dr. Karl Thomae GmbH (DE) 1986-12-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12492195-B2 Preparation method for and crystal form of 3-aryloxy-3-five-membered heteroaryl-propylamine compound TRPC7, TRPV1, TRPC5 TAAR1 337/4885MEN1 1938/4885KMT2A 3774/4885
US-20040249170-A1 Process for preparing an intermediate useful for the asymmetric synthesis of duloxetine PNMT, HTR1A, TPH1 TAAR1 251/4885MEN1 3661/4885KMT2A 896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.